Novocure Reports First Quarter 2018 Financial Results and Provides Company Update

2,009 active patients at March 31, 2018, an increase of 59 percent versus March 31, 2017 Delivered quarterly net revenues of $52.1 million, representing 49 percent growth versus the first quarter 2017 NCCN guidelines updated to recommend Optune in combination with temozolomide as a category 1 treatment for newly diagnosed glioblastoma Positive topline results from …

Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma

Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints Novocure plans to submit a Humanitarian Device Exemption application to the FDA for approval ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today positive top-line results from its STELLAR phase 2 pilot trial in mesothelioma demonstrating clinically meaningful improvements in overall …

Novocure to Report First Quarter 2018 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2018 on Thursday, April 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2018, at 8 …